Phase I study of GC33 in patients with Advanced Hepatocellular Carcinoma (HCC)
Phase 1
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Registration Number
- JPRN-jRCT2080221218
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
ECOG Performance Status of 0-1
-Histologically confirmed hepatocellular carcinoma(without fibrolamellar subtype)
-Child-Pugh A or B
Exclusion Criteria
-Child-Pugh
-Patients with significant central nervous system disorder caused by hepatic encephalopathy
-Patients with uncontrolable ascites
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method